Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

European cities plead for more flu shots as winter looms, pandemic rages

10/22/2020 | 12:34pm EST

(Adds Mylan response)

WARSAW/MILAN/VIENNA, Oct 22 (Reuters) - A surge in demand for vaccines to ward off the winter flu has led to shortages in some European cities, raising the risk of a potentially lethal "twindemic" as COVID-19 cases soar.

Many governments boosted vaccine orders this year and launched campaigns to encourage citizens to get shots.

The aim was to inoculate earlier than usual and cover a bigger portion of the continent's 450 million population to reduce the burden on health services.

Top manufacturers such as GlaxoSmithKline, Sanofi , Abbott and Seqirus have boosted supplies to the region by an average of 30% in anticipation of higher demand. But they are operating at full capacity and cannot meet all the late extra demand, Vaccines Europe, which represents the producers, said in a statement on Wednesday.

Interviews with at least 10 city and government officials, as well as medical experts, also show systems in major cities such as Warsaw are struggling with the strong early demand, causing delays and temporary shortages.

"This year, patients come all the time and ask about vaccines, more than 10 people every day," said Grazyna Lenkowska-Mielniczuk, manager at Apteka Non Stop pharmacy in Warsaw's Wola district.

"The wholesalers tell us the same thing as we tell patients: that there are no vaccines and we have to wait."

SEASONAL RISK

Europe's flu season begins in October and infections typically pick up between mid-November and the start of December, according to data from the European Centre for Disease Prevention and Control.

Seasonal flu viruses cause between 4 million and 50 million infections each year and up to 70,000 Europeans die each year of causes linked to flu, particularly among older adults and at-risk groups.

Precautionary measures to curb COVID-19 transmission such as social distancing, mask wearing and hand washing may help curb infections this season.

There was "very limited" flu transmission in the southern hemisphere this year for that reason, Sylvie Briand, director of Global Infectious Hazard Preparedness at the World Health Organization said in a briefing last week.

Even so, surging coronavirus infections across the continent prompted EU Health Commissioner Stella Kyriakides to warn last month of the risk of a "twindemic of COVID-19 and the flu".

Medical experts are urging more people get inoculated to prevent a deeper crisis.

"There is a need to prevent a double wave of influenza plus COVID-19," said Clemens Wendtner, chief physician of infectiology and tropical medicine at the Munich Schwabing Clinic, who recommends people younger than 60 get the jab this year.

PLEADING FOR SUPPLIES

Poland's Ministry of Health said it bought 3 million doses this year and will buy more if needed - as of Tuesday it had received 1.6 million shots.

But Mylan's Influvac Tetra and Sanofi's Vaxigrip Tetra vaccines are available in only 1% of pharmacies in Poland, according to gdziepolek.pl, a Polish website that helps patients find the nearest pharmacy with a drug they are seeking.

GSK's Fluarix Tetra is not available and AstraZeneca's Fluenz Tetra is available in 5% of pharmacies, the website showed.

A spokeswoman for Mylan said that the company was able to meet supply commitments in Poland and was monitoring supply levels. An AstraZeneca spokesman said the company was not aware of supply issues.

The disruption is being felt elsewhere in Europe.

In Belgium, one-third of ordered vaccines have not yet been delivered and some will arrive later than usual, according to the country's drugs agency. The government has booked nearly 3 million vaccines this year, 10% more than last year.

In Klagenfurt, a southern Austrian city of 100,000, authorities said in a statement they had made their usual order for vaccines in January, and tried unsuccessfully to increase their quota as the pandemic hit.

"There is already a severe shortage of influenza vaccines throughout Austria and there is an acute need for action," said city councillor Franz Petritz.

The Austrian government ordered 1.25 million shots for its population of almost 9 million, 60% more than last year, the Ministry of Social Affairs said.

Doses only started arriving in mid- to-late September and are taking time to reach vaccination centres around the country, it said, adding it was unclear if more would be needed.

DRUGMAKERS RAMP UP

Given the long lead times needed for flu vaccines to be produced, manufacturers made all possible efforts to increase production in the exceptional circumstances, Vaccines Europe said. But capacity to make more now is limited.

Allocation of doses to countries typically takes place a year or more ahead of a flu season and production for the northern hemisphere starts in early March.

The short shelf life also makes it difficult to adjust to unforeseen circumstances, a GSK spokeswoman said.

The company is looking to produce and distribute more for 2020 and the coming years, but demand is expected to continue to outpace manufacturing capacity, she said.

Sanofi and AstraZeneca are delivering record volumes and have made extra supply available, spokespeople for the drug makers said.

Demand for flu vaccine doses in Italy increased by more than 40% from last year to 17 million, said Massimo Scaccabarozzi, president of the Italian pharmaceutical companies' association.

But some local authorities only started ordering supplies this month.

"We have already reached the limit of our industrial possibilities," said Scaccabarozzi. "I do not know if and how much it will be possible to further increase the quantity if there were further requests." (Reporting by Alicja Ptak in Warsaw, Emilio Parodi in Milan, Francois Murphy in Vienna, Ludwig Burger in Frankfurt and Julie Steenhuysen in Chicago; Additional reporting by Francesco Guarascio in Brussels, Caroline Copley in Berlin, Alistair Smout in London and Stephanie Nebehay in Geneva; Writing by Josephine Mason in London; Editing by Alex Richardson)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.76% 7937 Delayed Quote.2.54%
GLAXOSMITHKLINE PLC 0.91% 1393.6 Delayed Quote.-22.37%
MYLAN N.V. 1.96% 15.855 Delayed Quote.-21.12%
SANOFI -0.07% 84.04 Real-time Quote.-6.16%
All news about GLAXOSMITHKLINE PLC
12/01U.S. plans for first COVID vaccines as pandemic deaths surge again
RE
12/01ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions..
AQ
12/01GLAXOSMITHKLINE : ViiV Healthcare and the Medicines Patent Pool expand access to..
AQ
11/26French health minister confirms vaccination could start by end of year
RE
11/25How will Canada's COVID-19 vaccine program work?
RE
11/25EXPLAINER : When and how will COVID-19 vaccines become available?
RE
11/24AstraZeneca Gears Up to Vaccinate the World Against Covid-19
DJ
11/23GLAXOSMITHKLINE : GSK starts phase 3 study of RSV maternal candidate vaccine
AQ
11/23GLAXOSMITHKLINE : GSK starts phase 3 study of RSV maternal candidate vaccine
PU
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
DJ
More news
Financials
Sales 2020 34 219 M 45 706 M 45 706 M
Net income 2020 4 855 M 6 485 M 6 485 M
Net Debt 2020 22 921 M 30 615 M 30 615 M
P/E ratio 2020 14,2x
Yield 2020 5,74%
Capitalization 69 370 M 92 552 M 92 657 M
EV / Sales 2020 2,70x
EV / Sales 2021 2,56x
Nbr of Employees 99 437
Free-Float 92,3%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 1 712,02 GBX
Last Close Price 13,94 GBX
Spread / Highest target 16 763%
Spread / Average Target 12 185%
Spread / Lowest Target 7 832%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-22.37%92 309
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415